JAC Advance Access originally published online on November 28, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 45-52
© 2003 The British Society for Antimicrobial Chemotherapy
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Departments of Medical Microbiology, 1 University Medical Center St Radboud, PO Box 9101, 6500 HB Nijmegen; 2 Canisius-Wilhelmina Hospital, PO Box 9015, 6500 GS, Nijmegen, The Netherlands
Received 5 November 2001; returned 4 June 2002; revised 1 July 2002; accepted 27 September 2002
In vitro susceptibilities of 36 zygomycete isolates, belonging to six genera, to itraconazole, posaconazole, voriconazole, terbinafine, amphotericin B and 5-fluorocytosine were determined by using a broth microdilution adaptation of the National Committee for Clinical Laboratory Standards M-38P reference method. The influence of incubation time on MIC values, and the performance of a spectrophotometric method for MIC determination in comparison with the visual reference method, were also evaluated. Amphotericin B was active against most of the isolates. All the isolates were highly resistant to 5-fluorocytosine (MICs > 256 mg/L). Voriconazole was significantly less active than the other drugs with an overall MIC90 (MIC at which 90% of the isolates were inhibited) of 32 mg/L. In contrast, posaconazole showed good activity (MIC90 1 mg/L). A wide range of MICs, from 0.03 to 
32 mg/L, was obtained for itraconazole and terbinafine. Differences in susceptibility between and within genera were noted. Rhizopus spp. were significantly less susceptible to itraconazole, posaconazole, terbinafine and amphotericin B than Absidia spp., and less susceptible than Mucor spp. to amphotericin B. Terbinafine appeared to be more active against Rhizopus microsporus than against Rhizopus oryzae (geometric mean MIC of 0.15 and 64 mg/L, respectively). The activity of the drugs was dependent on the incubation period. A significant increase in MICs was noted between 24 and 48 h of incubation. On the other hand, the two methods used for MIC determination (visual and spectrophotometric readings) showed good agreement. These results suggest that the zygomycetes are a heterogeneous group for antifungal susceptibility. Some of the conventional and new antifungals are effective in vitro; their efficacies in vivo remain to be determined. The spectrophotometric method appears to be a valuable alternative to the visual method for MIC determination for zygomycetes.
* Corresponding author. Tel: +31-24-361-43-56; Fax: +31-24-354-02-16; E-mail: p.verweij{at}mmb.azn.nl
Members of The Eurofung Network are listed in the Acknowledgements.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. ESPOSITO, R. VIGLIETTI, M. GARGIULO, R. PARRELLA, M. ONOFRIO, V. SANGIOVANNI, D. AMBROSINO, and A. CHIRIANNI Successful Treatment of Cryptococcal Meningitis with a Combination of Liposomal Amphotericin B, Flucytosine and Posaconazole: Two Case Reports In Vivo, May 1, 2009; 23(3): 465 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Balajee, A. M. Borman, M. E. Brandt, J. Cano, M. Cuenca-Estrella, E. Dannaoui, J. Guarro, G. Haase, C. C. Kibbler, W. Meyer, et al. Sequence-Based Identification of Aspergillus, Fusarium, and Mucorales Species in the Clinical Mycology Laboratory: Where Are We and Where Should We Go from Here? J. Clin. Microbiol., April 1, 2009; 47(4): 877 - 884. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Alastruey-Izquierdo, M. V. Castelli, I. Cuesta, A. Monzon, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela Activity of Posaconazole and Other Antifungal Agents against Mucorales Strains Identified by Sequencing of Internal Transcribed Spacers Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1686 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. U. Khan, S. Ahmad, A. Brazda, and R. Chandy Mucor circinelloides as a Cause of Invasive Maxillofacial Zygomycosis: an Emerging Dimorphic Pathogen with Reduced Susceptibility to Posaconazole J. Clin. Microbiol., April 1, 2009; 47(4): 1244 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Perkhofer, M. Locher, M. Cuenca-Estrella, R. Ruchel, R. Wurzner, M. P. Dierich, and C. Lass-Florl Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2636 - 2638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Espinel-Ingroff and E. Canton Comparison of Neo-Sensitabs Tablet Diffusion Assay with CLSI Broth Microdilution M38-A and Disk Diffusion Methods for Testing Susceptibility of Filamentous Fungi with Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole J. Clin. Microbiol., May 1, 2008; 46(5): 1793 - 1803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. de la Escalera, A. I. Aller, E. Lopez-Oviedo, A. Romero, A. I. Martos, E. Canton, J. Peman, P. G. Martos, and E. Martin-Mazuelos Activity of BAL 4815 against filamentous fungi J. Antimicrob. Chemother., May 1, 2008; 61(5): 1083 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Soummer, A. Mathonnet, O. Scatton, P. P. Massault, A. Paugam, V. Lemiale, J. P. Mira, E. Dannaoui, A. Cariou, and O. Lortholary Failure of Deferasirox, an Iron Chelator Agent, Combined with Antifungals in a Case of Severe Zygomycosis Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1585 - 1586. [Full Text] [PDF]
|
|
|
|
|
|
A. Espinel-Ingroff, E. Johnson, H. Hockey, and P. Troke Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies J. Antimicrob. Chemother., March 1, 2008; 61(3): 616 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Almyroudis, D. A. Sutton, A. W. Fothergill, M. G. Rinaldi, and S. Kusne In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2587 - 2590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Espinel-Ingroff, B. Arthington-Skaggs, N. Iqbal, D. Ellis, M. A. Pfaller, S. Messer, M. Rinaldi, A. Fothergill, D. L. Gibbs, and A. Wang Multicenter Evaluation of a New Disk Agar Diffusion Method for Susceptibility Testing of Filamentous Fungi with Voriconazole, Posaconazole, Itraconazole, Amphotericin B, and Caspofungin J. Clin. Microbiol., June 1, 2007; 45(6): 1811 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Schwarz, O. Lortholary, F. Dromer, and E. Dannaoui Carbon Assimilation Profiles as a Tool for Identification of Zygomycetes J. Clin. Microbiol., May 1, 2007; 45(5): 1433 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Torres-Narbona, J. Guinea, J. Martinez-Alarcon, T. Pelaez, and E. Bouza In Vitro Activities of Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole against 45 Clinical Isolates of Zygomycetes: Comparison of CLSI M38-A, Sensititre YeastOne, and the Etest Antimicrob. Agents Chemother., March 1, 2007; 51(3): 1126 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Espinel-Ingroff Comparison of Three Commercial Assays and a Modified Disk Diffusion Assay with Two Broth Microdilution Reference Assays for Testing Zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with Posaconazole and Amphotericin B J. Clin. Microbiol., October 1, 2006; 44(10): 3616 - 3622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sabatelli, R. Patel, P. A. Mann, C. A. Mendrick, C. C. Norris, R. Hare, D. Loebenberg, T. A. Black, and P. M. McNicholas In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2009 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sansone-Parsons, G. Krishna, A. Calzetta, D. Wexler, B. Kantesaria, M. A. Rosenberg, and M. A. Saltzman Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1881 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzon, and J. L. Rodriguez-Tudela Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi Antimicrob. Agents Chemother., March 1, 2006; 50(3): 917 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Machouart, J. Larche, K. Burton, J. Collomb, P. Maurer, A. Cintrat, M. F. Biava, S. Greciano, A. F. A. Kuijpers, N. Contet-Audonneau, et al. Genetic Identification of the Main Opportunistic Mucorales by PCR-Restriction Fragment Length Polymorphism. J. Clin. Microbiol., March 1, 2006; 44(3): 805 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Ullmann, O. A. Cornely, A. Burchardt, R. Hachem, D. P. Kontoyiannis, K. Topelt, R. Courtney, D. Wexler, G. Krishna, M. Martinho, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother., February 1, 2006; 50(2): 658 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Schwarz, S. Bretagne, J.-C. Gantier, D. Garcia-Hermoso, O. Lortholary, F. Dromer, and E. Dannaoui Molecular Identification of Zygomycetes from Culture and Experimentally Infected Tissues J. Clin. Microbiol., February 1, 2006; 44(2): 340 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Antachopoulos, J. Meletiadis, E. Roilides, T. Sein, and T. J. Walsh Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay J. Clin. Microbiol., February 1, 2006; 44(2): 553 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Chamilos, R. E. Lewis, and D. P. Kontoyiannis Lovastatin Has Significant Activity against Zygomycetes and Interacts Synergistically with Voriconazole Antimicrob. Agents Chemother., January 1, 2006; 50(1): 96 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Greenberg, K. Mullane, J.-A. H. van Burik, I. Raad, M. J. Abzug, G. Anstead, R. Herbrecht, A. Langston, K. A. Marr, G. Schiller, et al. Posaconazole as Salvage Therapy for Zygomycosis Antimicrob. Agents Chemother., January 1, 2006; 50(1): 126 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Pimentel, G. Dreyer, and G. D. Lum Peritonitis due to Cunninghamella bertholletiae in a patient undergoing continuous ambulatory peritoneal dialysis J. Med. Microbiol., January 1, 2006; 55(1): 115 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Brown Zygomycosis: An emerging fungal infection Am. J. Health Syst. Pharm., December 15, 2005; 62(24): 2593 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pitisuttithum, R. Negroni, J. R. Graybill, B. Bustamante, P. Pappas, S. Chapman, R. S. Hare, and C. J. Hardalo Activity of posaconazole in the treatment of central nervous system fungal infections J. Antimicrob. Chemother., October 1, 2005; 56(4): 745 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Spellberg, J. Edwards Jr., and A. Ibrahim Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management Clin. Microbiol. Rev., July 1, 2005; 18(3): 556 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fortun, P. Martin-Davila, E. Navas, M. J. Perez-Elias, J. Cobo, M. Tato, E. G.-G. De la Pedrosa, E. Gomez-Mampaso, and S. Moreno Linezolid for the treatment of multidrug-resistant tuberculosis J. Antimicrob. Chemother., July 1, 2005; 56(1): 180 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gil-Lamaignere, R. Hess, S. Salvenmoser, K. Heyn, R. Kappe, and F.-M. C. Muller Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes J. Antimicrob. Chemother., June 1, 2005; 55(6): 1016 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Ibrahim, J. C. Bowman, V. Avanessian, K. Brown, B. Spellberg, J. E. Edwards Jr., and C. M. Douglas Caspofungin Inhibits Rhizopus oryzae 1,3-{beta}-D-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis Antimicrob. Agents Chemother., February 1, 2005; 49(2): 721 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller and D. J. Diekema Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus J. Clin. Microbiol., October 1, 2004; 42(10): 4419 - 4431. [Full Text] [PDF]
|
|
|
|
|
|
C. Lass-Florl, M. Fille, E. Gunsilius, G. Gastl, and D. Nachbaur Disseminated Infection with Prototheca zopfii after Unrelated Stem Cell Transplantation for Leukemia J. Clin. Microbiol., October 1, 2004; 42(10): 4907 - 4908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Frippiat, C. Bergiers, C. Michel, J.-P. Dujardin, and G. Derue Severe bilateral optic neuritis associated with prolonged linezolid therapy J. Antimicrob. Chemother., June 1, 2004; 53(6): 1114 - 1115. [Full Text] [PDF]
|
|
|
|
|
|
E. Dannaoui, J. F. G. M. Meis, D. Loebenberg, and P. E. Verweij Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3647 - 3650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Meletiadis, D. T. A. te Dorsthorst, and P. E. Verweij Use of Turbidimetric Growth Curves for Early Determination of Antifungal Drug Resistance of Filamentous Fungi J. Clin. Microbiol., October 1, 2003; 41(10): 4718 - 4725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Diekema, S. A. Messer, R. J. Hollis, R. N. Jones, and M. A. Pfaller Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi J. Clin. Microbiol., August 1, 2003; 41(8): 3623 - 3626. [Abstract] [Full Text] [PDF]
|
|